Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.

Hdl Handle:
http://hdl.handle.net/10147/294667
Title:
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
Authors:
Mohd Sharial, M S N; Crown, J; Hennessy, B T
Affiliation:
Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
Citation:
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. 2012, 23 (12):3007-16 Ann. Oncol.
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Issue Date:
Dec-2012
URI:
http://hdl.handle.net/10147/294667
DOI:
10.1093/annonc/mds200
PubMed ID:
22865781
Abstract:
Approximately 15%-23% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), which leads to the activation of signaling pathways that stimulate cell proliferation and survival. HER2-targeted therapy has substantially improved outcomes in patients with HER2-positive breast cancer. However, both de novo and acquired resistance are observed.
Item Type:
Article
Language:
en
MeSH:
Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Receptor, erbB-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases
ISSN:
1569-8041

Full metadata record

DC FieldValue Language
dc.contributor.authorMohd Sharial, M S Nen_GB
dc.contributor.authorCrown, Jen_GB
dc.contributor.authorHennessy, B Ten_GB
dc.date.accessioned2013-06-26T13:26:45Z-
dc.date.available2013-06-26T13:26:45Z-
dc.date.issued2012-12-
dc.identifier.citationOvercoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. 2012, 23 (12):3007-16 Ann. Oncol.en_GB
dc.identifier.issn1569-8041-
dc.identifier.pmid22865781-
dc.identifier.doi10.1093/annonc/mds200-
dc.identifier.urihttp://hdl.handle.net/10147/294667-
dc.description.abstractApproximately 15%-23% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), which leads to the activation of signaling pathways that stimulate cell proliferation and survival. HER2-targeted therapy has substantially improved outcomes in patients with HER2-positive breast cancer. However, both de novo and acquired resistance are observed.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.subject.meshAntibodies, Monoclonal, Humanized-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCell Proliferation-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunosuppressive Agents-
dc.subject.meshPhosphatidylinositol 3-Kinase-
dc.subject.meshProto-Oncogene Proteins c-akt-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshSignal Transduction-
dc.subject.meshSirolimus-
dc.subject.meshTOR Serine-Threonine Kinases-
dc.titleOvercoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland.en_GB
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.